ProCE Banner Series

Management of Eosinophilic Esophagitis: Opportunities for Pharmacists to Increase Awareness and Optimize Care

EoE remains underrecognized and undertreated, despite availability of an FDA-approved therapy. Join us to hear the latest expert updates on pharmacists’ important role in collaborative EoE care to optimize overall management, patient and disease outcomes, and healthcare transitions.

  ACPE-P
Credits Available

1.5 ACPE-P

Who Should Attend

Pharmacists, including managed care, specialty, and clinical pharmacists, who care for patients with EoE, as well as pharmacy directors, chief pharmacy officers, and other stakeholders in pharmacy practice.

All Events

Management of Eosinophilic Esophagitis: Opportunities for Pharmacists to Increase Awareness and Optimize Care

Past Events

March

23

2023

6:00 AM - 8:00 AM Central Time (CT)

In-personVirtual

Henry B. González Convention Center, 900 E Market St., San Antonio, Texas 78205

Faculty

ProCE Banner Faculty
Brian A. Hemstreet, PharmD, FCCP, BCPS

Associate Dean and Professor
Department of Clinical Pharmacy
University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences
Aurora, Colorado

ProCE Banner Faculty
Erin Hamai Tom, PharmD, APh, MBA, BCACP, CSP

Clinical Manager
Specialty Pharmacy
UC Davis Health
Sacramento, California

Topics

Management of Eosinophilic Esophagitis: Opportunities for Pharmacists to Increase Awareness and Optimize Care

Additional Info

There are no fees required to participate in this activity.

Americans With Disabilities Act 
Event staff will be glad to assist you with any special needs (eg, physical, dietary). Please contact meetings@clinicaloptions.com prior to the live event.

CME/CE Info

Program Overview
EoE remains underrecognized and undertreated, despite availability of an FDA-approved therapy. Join us to hear the latest expert updates on pharmacists’ important role in collaborative EoE care to optimize overall management, patient and disease outcomes, and healthcare transitions.  

Goal Statement
The goal of this activity is to improve the knowledge and competence of learners about EoE, treatment options, and the role of the pharmacist in EoE management to improve patient outcomes. 

Target Audience
This activity is intended for pharmacists, including managed care, specialty, and clinical pharmacists, who care for patients with EoE, as well as pharmacy directors, chief pharmacy officers, and other stakeholders in pharmacy practice. 

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Describe the pathophysiology and burden of disease in EoE
  • Evaluate current and emerging therapies based on their impact on disease outcomes in patients with EoE
  • Identify strategies for coordinating with the multidisciplinary team to improve health-related quality of life and outcomes for patients with EoE
  • Discuss the role of the pharmacist in EoE disease management, including in transitions of care

 

Accreditation

CE Accreditation

Pharmacists

ProCE, LLC is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. ACPE Universal Activity Number 0221-0000-23-004-L01-P has been assigned to this live application-based activity (initial release date 03/23/2023). This activity is approved for 1.50 contact hours (0.15 CEU) in states that recognize ACPE providers. This activity is provided at no cost to participants. Participants must complete the online post-test and activity evaluation within 30 days of the activity to receive pharmacy CE credit. No partial credit will be given. Statements of completion will be issued online at www.ProCE.com, and proof of completion will be posted in NABP CPE Monitor profiles.

Disclosure
ProCE requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to ProCE policy. ProCE is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

Acknowledgement

Provided by ProCE, LLC.

This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc. and Sanofi.